Korean J Dermatol.  2013 Oct;51(10):776-781.

Immunohistochemical Study for the Syndecan-2 in Cutaneous Melanoma and Pigmented Nevus

Affiliations
  • 1Department of Dermatology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. cse@amc.seoul.kr
  • 2Dermatology Lab, Asan Institute for Life Science, Seoul, Korea.
  • 3University of Ulsan College of Medicine, Seoul, Korea.
  • 4Research Institute of Obesity Science, Sung Shin Womens University, Seoul, Korea.

Abstract

BACKGROUND
Melanoma is a malignant neoplasm originating from melanocytes. It has been recently suggested that syndecan-2 may contribute to the aggressive phenotype and metastatic potential of melanoma in cell line studies. However, there is no quantitative analysis of syndecan-2 expression using human melanoma tissue.
OBJECTIVE
This study aimed to examine the specific expression of syndecan-2 in human melanoma tissue.
METHODS
A total of 35 sections of formalin-fixed, paraffin-embedded tissues were investigated for syndecan-2 expression using immunohistochemical staining. Also, a total of 6 tissues and two kinds of cell lines were analyzed by reverse-transcriptase polymerase chain reaction (RT-PCR) and western blot.
RESULTS
Immunohistochemical staining of 23 cases of melanoma tissue was done, and in 5 cases (21.7%), strong expression of syndecan-2 was seen. Also, syndecan-2 was detected in human melanoma tissue and MNT-1 melanoma cells by RT-PCR and western blot analysis.
CONCLUSION
We suggest that syndecan-2 expression is increased in melanoma compared to nevus. The results of this study may help to explain the clinical features of melanoma and syndecan-2.

Keyword

Melanoma; Syndecan-2

MeSH Terms

Blotting, Western
Cell Line
Humans
Melanocytes
Melanoma*
Nevus
Nevus, Pigmented*
Phenotype
Polymerase Chain Reaction
Syndecan-2*
Syndecan-2
Full Text Links
  • KJD
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr